bioMerieux S.A.

Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
  • TickerBIM
  • ISINFR0013280286
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Christophe-Raphaël Ganet ...
  • Johanna Jourdain
  • Matthias Desmarais
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/10/2019

...

Christophe-Raphaël Ganet ...
  • Johanna Jourdain
  • Matthias Desmarais
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 10/09/2019

Depuis notre étude du 6 mai dernier « favoriser l’innovation et le recentrage Pharma », le Stoxx 600 Healthcare a progressé de 8.7% vs -0.4% pour le Stoxx 600. Cette performance est notamment expliquée par des publications du S1 de bonne facture. Cependant tributaire des annonces de reformes potentielles de la santé américaine, nous considérons toujours que le secteur devrait rester volatil dans ces prochains mois. Nous maintenons dans ce contexte notre préférence pour AstraZeneca (PE...

Christophe-Raphaël Ganet

bioMerieux : Pretty encouraging prospects, but the valuation is fairly high

>A very reassuring tone on the guidance for 2019 - Key takeaways from our road show with management: 1/ a reassuring stance and even a concerted and optimistic tone on the growth outlook for H2 2019: H1 came in at 5.5% l-f-l, and the guidance for 7/8.5% is maintained; this implies over 8% l-f-l in H2. Growth is set to be based on: i/ a return to normal for molecular biology / BioFire, as begun in Q2 (Q2: +29% vs Q1: +10% l-f-l), ii/ an end to the temporary diffic...

Christophe-Raphaël Ganet

bioMérieux : Perspectives plutôt encourageantes – Valorisation plutôt haute

>Tonalité très rassurante face aux guidances 2019 - De notre roadshow avec le management, nous retenons les points suivants : 1/ un discours rassurant voire, volontaire et optimiste sur la croissance du second semestre 2019: en effet, alors que le S1 ressort à 5,5% lfl. et que la guidance est maintenue à 7/8.5%; BIM induit donc un S2 >8% lfl. Une telle croissance reposerait sur i/ le retour à la normale de la biologie moléculaire / BioFire, engagé au T2 (cf. T2: ...

Christophe-Raphaël Ganet

bioMerieux : Pretty encouraging prospects, but the valuation is fairly high

>A very reassuring tone on the guidance for 2019 - Key takeaways from our road show with management: 1/ a reassuring stance and even a concerted and optimistic tone on the growth outlook for H2 2019: H1 came in at 5.5% l-f-l, and the guidance for 7/8.5% is maintained; this implies over 8% l-f-l in H2. Growth is set to be based on: i/ a return to normal for molecular biology / BioFire, as begun in Q2 (Q2: +29% vs Q1: +10% l-f-l), ii/ an end to the temporary diffic...

Christophe-Raphaël Ganet

bioMérieux : Perspectives plutôt encourageantes – Valorisation plutôt haute

>Tonalité très rassurante face aux guidances 2019 - De notre roadshow avec le management, nous retenons les points suivants : 1/ un discours rassurant voire, volontaire et optimiste sur la croissance du second semestre 2019: en effet, alors que le S1 ressort à 5,5% lfl. et que la guidance est maintenue à 7/8.5%; BIM induit donc un S2 >8% lfl. Une telle croissance reposerait sur i/ le retour à la normale de la biologie moléculaire / BioFire, engagé au T2 (cf. T2: ...

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - BIOMERIEUX (VENTE, OC 60€ vs 59€) : Pas d'excès d'optimisme après un S1 sans surprise

Cecile De Coincy ...
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • François Maury
  • Georges Dieng
  • Jean Sassus
  • Michael Foundoukidis
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/04/2019

...

Christophe-Raphaël Ganet

bioMerieux : Q2 sales: recovery in molecular biology – H1 underlying operating income in line with forecasts, confirming the guidance trajectory

>Q2 sales: recovery in molecular biology - H1 underlying operating income: in line - Revenues amounted to € 643.5m in Q2 (+10.5% and +7.4% l-f-l.), and € 1,275m in H1, i.e. +9.1%/+5.5% l-f-l at end-June (consensus: € 1,265m est. and +5.8%e l-f-l.).In H1, underlying operating income amounted to € 198m (consensus: € 196m), and net income to € 141m (effect of a slight increase in interest expense and a rise in the tax rate to 20.8% vs 19.1%).bioMérieux confirme...

1 director sold

A director at Biomerieux sold 8,000 shares at 73.514EUR and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Christophe-Raphaël Ganet ...
  • Johanna Jourdain
  • Matthias Desmarais
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/10/2019

...

Christophe-Raphaël Ganet ...
  • Johanna Jourdain
  • Matthias Desmarais
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 10/09/2019

Depuis notre étude du 6 mai dernier « favoriser l’innovation et le recentrage Pharma », le Stoxx 600 Healthcare a progressé de 8.7% vs -0.4% pour le Stoxx 600. Cette performance est notamment expliquée par des publications du S1 de bonne facture. Cependant tributaire des annonces de reformes potentielles de la santé américaine, nous considérons toujours que le secteur devrait rester volatil dans ces prochains mois. Nous maintenons dans ce contexte notre préférence pour AstraZeneca (PE...

Alfred Glaser ...
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Jerôme Bodin
  • Laurence Hofmann
  • Martial Descoutures
  • Michael Foundoukidis
  • Pierre Tegner
  • Pierre Corby
  • Roland Pfaender
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 24/04/2019

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/19/2019

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 19/03/2019

...

BIOMERIEUX SA sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to BIOMERIEUX SA (FR), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date January 15, 2019, the closing price was EUR 58.50 and its target price was estimated at EUR 51.22.

MarketLine Department

Bio-Rad Laboratories, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Bio-Rad Laboratories, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bio-Rad Laboratories, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

MarketLine Department

Great Basin Scientific Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Great Basin Scientific Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Great Basin Scientific Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

Charles Pinel

Biomérieux - Assemblée générale des actionnaires du 23 mai 2019

Il convient de féliciter la société qui propose l'approbation des différentes nouvelles conventions réglementées dans des résolutions spécifiques, ce qui permet aux actionnaires de les approuver de façon séparée. En revanche, il est regrettable que les conventions anciennes qui se poursuivent ne soient pas soumises à l'approbation des actionnaires (résolutions 5 à 7). Le nombre de membres du conseil passera de 11 à 9 à l'issue de l'assemblée générale. Bien que la famille Mérieux n'y détienne qu'un seul siège alors qu'elle possède 59% du capital, il demeure composé d'une majorité de membres no...

Expert Corporate Governance Service (ECGS)

BioMérieux - AGM and EGM 23 May 2019

ITEMS 5 to 7: The Company seeks shareholder approval of various new regulated agreements. ECGS notes that these agreements are in separate resolutions, which allows shareholders to vote on each one of them. However, we regret that the previous agreements that are still ongoing, are not subject to shareholder approval.  ITEM 9: After the Annual General Meeting, the number of Board members will be decreased from 11 to 9. Although the Mérieux family holds 59% of the capital and the board will still be composed by a majority of members that are not considered independent. This leads ECGS to OPPOS...

Proxy Report - 17/05/2018

La fin de l'exercice 2017 fût marquée par la nomination d'Alexandre Mérieux, ancien Directeur Général Délégué de la société, en qualité de Président-Directeur Général pour succéder à Jean-Luc Bélingard. Il est regrettable que la société n'ait pas profité de ce changement au sein de la direction pour séparer les fonctions de Président et de Directeur Général. Cette année encore, Proxinvest ne soutiendra pas la rémunération attribuée à Jean-Luc Bélingard et Alexandre Mérieux pour des raisons similaires à l'année dernière (Résolution 10 et 11) : une rémunération différée revue à la hausse sur la...

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 70,40 € prochainement. Le prochain objectif est à 63,02 €, puis 58,70 €. Le franchissement de 74,56 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BIOMERIEUX : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €70.40. The next target is at €63.02, then €58.70. Passing €74.56 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 63,02 €. La tendance baissière serait remise en cause au-dessus de 74,56 €.

Jérôme VINERIER

Short term view - BIOMERIEUX : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €63.02. The bearish trend would be challenged above €74.56.

Jérôme VINERIER

Analyse moyen terme - BIOMERIEUX : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch